[go: up one dir, main page]

DE19755268A1 - Benzamidinderivate - Google Patents

Benzamidinderivate

Info

Publication number
DE19755268A1
DE19755268A1 DE19755268A DE19755268A DE19755268A1 DE 19755268 A1 DE19755268 A1 DE 19755268A1 DE 19755268 A DE19755268 A DE 19755268A DE 19755268 A DE19755268 A DE 19755268A DE 19755268 A1 DE19755268 A1 DE 19755268A1
Authority
DE
Germany
Prior art keywords
methyl
oxazolidin
ylmethyl
phenyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19755268A
Other languages
German (de)
English (en)
Inventor
Dieter Dr Dorsch
Horst Dr Juraszyk
Hanns Dr Wurziger
Joachim Prof Gante
Werner Dr Mederski
Hans-Peter Dr Buchstaller
Soheila Dr Anzali
Sabine Dr Bernotat-Danielowski
Guido Dr Melzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to DE19755268A priority Critical patent/DE19755268A1/de
Priority to EP98964455A priority patent/EP1056743A1/fr
Priority to HU0004353A priority patent/HUP0004353A3/hu
Priority to BR9813477-9A priority patent/BR9813477A/pt
Priority to PCT/EP1998/007673 priority patent/WO1999031092A1/fr
Priority to CA002313651A priority patent/CA2313651A1/fr
Priority to PL98341008A priority patent/PL341008A1/xx
Priority to SK857-2000A priority patent/SK8572000A3/sk
Priority to CN98812087A priority patent/CN1281451A/zh
Priority to RU2000118792/04A priority patent/RU2203897C2/ru
Priority to KR1020007006310A priority patent/KR20010032963A/ko
Priority to JP2000539016A priority patent/JP2002508370A/ja
Priority to AU19647/99A priority patent/AU744002B2/en
Priority to ZA9811339A priority patent/ZA9811339B/xx
Priority to ARP980106293A priority patent/AR017844A1/es
Publication of DE19755268A1 publication Critical patent/DE19755268A1/de
Priority to NO20002958A priority patent/NO20002958L/no
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
DE19755268A 1997-12-12 1997-12-12 Benzamidinderivate Withdrawn DE19755268A1 (de)

Priority Applications (16)

Application Number Priority Date Filing Date Title
DE19755268A DE19755268A1 (de) 1997-12-12 1997-12-12 Benzamidinderivate
SK857-2000A SK8572000A3 (en) 1997-12-12 1998-11-27 Benzamine derivatives
KR1020007006310A KR20010032963A (ko) 1997-12-12 1998-11-27 벤즈아민 유도체
BR9813477-9A BR9813477A (pt) 1997-12-12 1998-11-27 Derivados de benzamidina
PCT/EP1998/007673 WO1999031092A1 (fr) 1997-12-12 1998-11-27 DERIVES DE BENZAMIDINE UTILISES COMME INHIBITEURS DU FACTEUR DE COAGULATION Xa
CA002313651A CA2313651A1 (fr) 1997-12-12 1998-11-27 Derives de benzamidine utilises comme inhibiteurs du facteur de coagulation xa
PL98341008A PL341008A1 (en) 1997-12-12 1998-11-27 Benzamidine derivatives
EP98964455A EP1056743A1 (fr) 1997-12-12 1998-11-27 DERIVES DE BENZAMIDINE UTILISES COMME INHIBITEURS DU FACTEUR DE COAGULATION Xa
CN98812087A CN1281451A (zh) 1997-12-12 1998-11-27 苄脒衍生物
RU2000118792/04A RU2203897C2 (ru) 1997-12-12 1998-11-27 Производные бензамидина, способ их получения, фармацевтическая композиция, способ ее получения и лекарственное средство
HU0004353A HUP0004353A3 (en) 1997-12-12 1998-11-27 Benzamine derivatives, process for producing them and ph
JP2000539016A JP2002508370A (ja) 1997-12-12 1998-11-27 ベンズアミジン誘導体
AU19647/99A AU744002B2 (en) 1997-12-12 1998-11-27 Benzamine derivatives
ZA9811339A ZA9811339B (en) 1997-12-12 1998-12-10 Benzamidine derivatives.
ARP980106293A AR017844A1 (es) 1997-12-12 1998-12-11 Derivados de benzamidina, procedimiento para prepararlos, empleo de los mismos para preparar un medicamento, composicion farmaceutica que los contiene yprocedimiento para obtenerla
NO20002958A NO20002958L (no) 1997-12-12 2000-06-09 Benzamidinderivater som koagulasjonsfaktor Xa-hemmere

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19755268A DE19755268A1 (de) 1997-12-12 1997-12-12 Benzamidinderivate

Publications (1)

Publication Number Publication Date
DE19755268A1 true DE19755268A1 (de) 1999-06-17

Family

ID=7851688

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19755268A Withdrawn DE19755268A1 (de) 1997-12-12 1997-12-12 Benzamidinderivate

Country Status (16)

Country Link
EP (1) EP1056743A1 (fr)
JP (1) JP2002508370A (fr)
KR (1) KR20010032963A (fr)
CN (1) CN1281451A (fr)
AR (1) AR017844A1 (fr)
AU (1) AU744002B2 (fr)
BR (1) BR9813477A (fr)
CA (1) CA2313651A1 (fr)
DE (1) DE19755268A1 (fr)
HU (1) HUP0004353A3 (fr)
NO (1) NO20002958L (fr)
PL (1) PL341008A1 (fr)
RU (1) RU2203897C2 (fr)
SK (1) SK8572000A3 (fr)
WO (1) WO1999031092A1 (fr)
ZA (1) ZA9811339B (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001092214A1 (fr) * 2000-05-31 2001-12-06 Merck Patent Gmbh Esters d'acide carbamique utilises comme inhibiteurs du facteur xa
WO2003047572A1 (fr) * 2001-12-04 2003-06-12 Merck Patent Gmbh Utilisation de composes 1-phenyl-oxazolidin-2-one comme inhibiteurs de la protease m
US6903085B1 (en) 1999-08-24 2005-06-07 Astrazeneca, Ab Substituted piperidine compounds useful as modulators of chemokine receptor activity
US6911458B2 (en) 2000-06-20 2005-06-28 Astra Zeneca Compounds
US6927222B2 (en) 2000-02-25 2005-08-09 Astrazeneca Ab Compounds
US6958350B2 (en) 2001-02-19 2005-10-25 Astrazeneca Ab Chemical compounds
US6960602B2 (en) 2001-03-22 2005-11-01 Astrazeneca Ab Piperidine derivatives as modulators of chemokine receptors
US7005439B2 (en) 2000-06-20 2006-02-28 Astrazeneca Ab Compounds
US7192973B2 (en) 2001-11-15 2007-03-20 Astrazeneca Ab Piperidine derivatives and their use as modulators of chemokine receptor activity (especially CCR5)
WO2007089101A1 (fr) * 2006-01-31 2007-08-09 Dong Wha Pharmaceutical Ind.Co., Ltd. Nouveaux dérivés de benzamidine, procédé de fabrication et composition pharmaceutique les renfermant
US7294636B2 (en) 2003-05-09 2007-11-13 Astrazeneca Ab Chemical compounds
US7345063B2 (en) 2001-03-23 2008-03-18 Astrazeneca Ab Amides, preparation and therapeutic use as modulators of CCR-receptor activity
US7388020B2 (en) 2001-03-19 2008-06-17 Astrazeneca Ab Benzimidazol derivatives modulate chemokine receptors
WO2009017346A1 (fr) * 2007-07-27 2009-02-05 Dong Wha Pharmaceutical Co., Ltd. Nouveaux dérivés de benzamidine, procédé de préparation correspondant et composition pharmaceutique les contenant qui permet de prévenir ou de traiter l'ostéoporose
US8148405B2 (en) 2005-08-02 2012-04-03 Astrazeneca Ab Salt I
US20130109672A1 (en) * 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5196399A (en) * 1998-08-11 2000-03-06 Daiichi Pharmaceutical Co., Ltd. Novel sulfonyl derivatives
AU2004202422B2 (en) * 1999-12-24 2007-11-22 Bayer Intellectual Property Gmbh Substituted oxazolidinones and their use in the field of blood coagulation
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10105989A1 (de) * 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
PL209135B1 (pl) * 2002-03-06 2011-07-29 Toyama Chemical Co Ltd Pochodna aryloamidyny lub jej sól oraz środek grzybobójczy
DK1569912T3 (en) 2002-12-03 2015-06-29 Pharmacyclics Inc 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10322469A1 (de) * 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
NZ544449A (en) * 2003-06-23 2008-10-31 Cv Therapeutics Inc Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
EP1685841A1 (fr) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention et traitement de troubles thromboemboliques
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
AU2006299126B2 (en) 2005-10-04 2012-06-28 Bayer Intellectual Property Gmbh Novel polymorphous form and the amorphous form of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
DE102007018662A1 (de) 2007-04-20 2008-10-23 Bayer Healthcare Ag Oxazolidinone zur Behandlung und Prophylaxe von pulmonaler Hypertonie
WO2008140220A1 (fr) * 2007-05-09 2008-11-20 Legochem Bioscience Ltd. Inhibiteurs du facteur xa comprenant des amidines cycliques en tant que sous-unité p4, leurs procédés de préparation, et compositions pharmaceutiques et dérivés de ceux-ci
KR101009594B1 (ko) 2007-05-09 2011-01-20 주식회사 레고켐 바이오사이언스 Ｐ4 위치에 사이클릭 아미딘을 가지는 ＦＸａ 저해제, 이의유도체, 제조방법 및 이를 함유하는 의약 조성물
DE102007028318A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Oxazolidinone zur Behandlung und Prophylaxe von Sepsis
EP2138178A1 (fr) 2008-06-28 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Oxazolidinones pour le traitement de maladie pulmonaire obstructive chronique (MPOC) et/ou de l'asthme
EP2140866A1 (fr) 2008-07-04 2010-01-06 Bayer Schering Pharma Aktiengesellschaft Oxazolidinones pour le traitement d'états inflammatoires du tractus gastro-intestinal
CN102822167A (zh) * 2010-01-04 2012-12-12 埃南蒂亚有限公司 用于制备利伐沙班的方法及其中间体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166132A (en) * 1977-08-18 1979-08-28 Pfizer Inc. Antiviral amine derivatives of glycerol and propanediols
DE4203201A1 (de) * 1992-02-05 1993-08-12 Boehringer Ingelheim Kg Neue amidinderivate, ihre herstellung und verwendung
DK0623615T3 (da) * 1993-05-01 1999-12-13 Merck Patent Gmbh Adhæsionsreceptor-antagonister
ATE170179T1 (de) * 1994-11-02 1998-09-15 Merck Patent Gmbh Adhäsionsrezeptor-antagonisten
DE19504954A1 (de) * 1995-02-15 1996-08-22 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19516483A1 (de) * 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
ATE267011T1 (de) * 1995-12-21 2004-06-15 Bristol Myers Squibb Pharma Co Isoxazolin, isothiazolin und pyrazolin als faktor xa inhibitoren
KR20010021645A (ko) * 1997-07-11 2001-03-15 로렌스 티. 마이젠헬더 티아디아졸릴 및 옥사디아졸릴 페닐 옥사졸리디논 항균제

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903085B1 (en) 1999-08-24 2005-06-07 Astrazeneca, Ab Substituted piperidine compounds useful as modulators of chemokine receptor activity
US6927222B2 (en) 2000-02-25 2005-08-09 Astrazeneca Ab Compounds
US6943188B2 (en) 2000-02-25 2005-09-13 Astrazeneca Ab Hydroxyalkyl compounds
US6951874B2 (en) 2000-02-25 2005-10-04 Astrazeneca Ab Compounds
WO2001092214A1 (fr) * 2000-05-31 2001-12-06 Merck Patent Gmbh Esters d'acide carbamique utilises comme inhibiteurs du facteur xa
US7528156B2 (en) 2000-06-20 2009-05-05 Astrazeneca Ab Compounds
US6911458B2 (en) 2000-06-20 2005-06-28 Astra Zeneca Compounds
US7005439B2 (en) 2000-06-20 2006-02-28 Astrazeneca Ab Compounds
US6958350B2 (en) 2001-02-19 2005-10-25 Astrazeneca Ab Chemical compounds
US7388020B2 (en) 2001-03-19 2008-06-17 Astrazeneca Ab Benzimidazol derivatives modulate chemokine receptors
US6960602B2 (en) 2001-03-22 2005-11-01 Astrazeneca Ab Piperidine derivatives as modulators of chemokine receptors
US7345063B2 (en) 2001-03-23 2008-03-18 Astrazeneca Ab Amides, preparation and therapeutic use as modulators of CCR-receptor activity
US7192973B2 (en) 2001-11-15 2007-03-20 Astrazeneca Ab Piperidine derivatives and their use as modulators of chemokine receptor activity (especially CCR5)
WO2003047572A1 (fr) * 2001-12-04 2003-06-12 Merck Patent Gmbh Utilisation de composes 1-phenyl-oxazolidin-2-one comme inhibiteurs de la protease m
US7294636B2 (en) 2003-05-09 2007-11-13 Astrazeneca Ab Chemical compounds
US8148405B2 (en) 2005-08-02 2012-04-03 Astrazeneca Ab Salt I
WO2007089101A1 (fr) * 2006-01-31 2007-08-09 Dong Wha Pharmaceutical Ind.Co., Ltd. Nouveaux dérivés de benzamidine, procédé de fabrication et composition pharmaceutique les renfermant
US7943646B2 (en) 2006-01-31 2011-05-17 Dong Wha Pharmaceutical Co., Ltd. Benzamidine derivative, process for the preparation thereof and pharmaceutical composition comprising same
WO2009017346A1 (fr) * 2007-07-27 2009-02-05 Dong Wha Pharmaceutical Co., Ltd. Nouveaux dérivés de benzamidine, procédé de préparation correspondant et composition pharmaceutique les contenant qui permet de prévenir ou de traiter l'ostéoporose
US20130109672A1 (en) * 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase
US9708267B2 (en) 2010-04-29 2017-07-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase

Also Published As

Publication number Publication date
JP2002508370A (ja) 2002-03-19
AU1964799A (en) 1999-07-05
AR017844A1 (es) 2001-10-24
ZA9811339B (en) 1999-07-08
WO1999031092A1 (fr) 1999-06-24
PL341008A1 (en) 2001-03-12
HUP0004353A2 (hu) 2002-03-28
HUP0004353A3 (en) 2002-04-29
AU744002B2 (en) 2002-02-14
NO20002958L (no) 2000-08-11
NO20002958D0 (no) 2000-06-09
EP1056743A1 (fr) 2000-12-06
KR20010032963A (ko) 2001-04-25
BR9813477A (pt) 2000-10-24
CA2313651A1 (fr) 1999-06-24
SK8572000A3 (en) 2001-07-10
RU2203897C2 (ru) 2003-05-10
CN1281451A (zh) 2001-01-24

Similar Documents

Publication Publication Date Title
DE19755268A1 (de) Benzamidinderivate
EP1025086B1 (fr) DERIVES DE BENZAMIDINE UTILISES COMME INHIBITEURS DU FACTEUR Xa
DE10063008A1 (de) Carbonsäureamidderivate
DE10102322A1 (de) Phenylderivate
DE10112768A1 (de) Phenylderivate 3
EP1157010A1 (fr) Derives de pyrazol-3-one utilises comme inhibiteurs du facteur xa
DE10155075A1 (de) Cyclische Sulfonamide
AU2004205354B2 (en) Carboxamide derivatives and their use as factor Xa inhibitors
DE10035144A1 (de) Cyclische Aminosäurederivate
DE10036121A1 (de) N-Substituierte-1-amino-1,1-dialkyl-carbonsäurederivate
DE10027025A1 (de) Clycinamide
WO2000008005A2 (fr) Derives de piperazinone
DE10027024A1 (de) Carbaminsäureester
DE10110325A1 (de) Phenylderivate 2
DE10037146A1 (de) Acetamidderivate
EP1480948A1 (fr) Derives de semicarbazides et leur utilisation en tant qu'antithrombotiques
DE10036852A1 (de) Urethanderivate
MXPA00003094A (en) Benzamidine derivatives as factor xa inhibitors
CZ20001183A3 (cs) Derivát benzamidinu jako inhibitor faktoru XA, způsob jeho přípravy, jeho použití a farmaceutický prostředek, který ho obsahuje
CZ20002126A3 (cs) Řešení se týká nosného tělesa (1) pro uspořádání elektrických kontaktů, které obsahuje elektricky nevodivé základní těleso, ve kterémjsou uspořádány elektrické kontakty (3). Nosné těleso (1) má modulovou konstrukci, sestávající z jednotlivých samostatných prvků (2,4), které mohou být spolu vzájemně sestaveny a spojeny. Jednotlivé samostatné prvky (2,4) mohou nebo nemusejí být opatřeny kontakty (3).

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee